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Background. The apolipoprotein (apo) B/apoA-I ratio represents the balance between apoB-rich atherogenic particles and apoA-
I-rich antiatherogenic particles, and this ratio is considered to be a marker of cardiovascular risk. Although many studies have
demonstrated the importance of the apoB/apoA-I ratio in predicting the presence or absence of cardiovascular disease, less is known
about apoB/apoA-I ratio as a marker of plasma atherogenicity.Methods. A total of 157 normolipidemic men aged 20–59 years were
included in the study.The plasma levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C),
apoA-I, apoB, and apoE were determined after a 12 h fasting period. Results. The median of the apoB/apoA-I ratio in the studied
normolipidemic subjects was 0.52, with values ranging from 0.19 to 2.60. The percentage of subjects with the apoB/apoA-I ratio
exceeding 0.9 (the accepted risk value of cardiovascular disease) was 19.1%.The subjects with apoB/apoA-I>0.9 were characterized
by higher TG levels and atherogenic index of plasma (AIP) and lower values of ratio of low-density lipoprotein cholesterol (LDL-
C) to apoB (LDL-C/apoB) and apoE levels compared with men with apoB/apoA-I<0.9. Conclusion. Despite normolipidemia, the
subjects with the unfavorable apoB/apoA-I ratio had more atherogenic lipid profile.
1. Introduction
Atherosclerosis is a pathologic process affecting blood vessels,
which leads to the development of cardiovascular disease
[1, 2]. Although atherogenesis is a multifactorial process,
abnormalities in lipid metabolism are a key factor, represent-
ing approximately 50% of the population-attributable risk
of developing cardiovascular disease [3]. The recent studies
have shown that using the conventional lipid indices can
result in errors in the assessment of cardiovascular risk [4–
6]. A considerable proportion of patients with atherosclerotic
disease has levels of total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-C) within the health-related
reference interval [7, 8], and some patients who achieve
significant LDL-C reduction with lipid-lowering therapy still
develop cardiovascular disease [9, 10].
The main cause of errors in the estimation of the
lipoprotein-related risk of cardiovascular disease when using
the conventional lipid indexes is due to the wide vari-
ance of cholesterol within the low-density lipoprotein and
high-density lipoprotein molecules; this variance is due to
the active exchange of lipid components between lipopro-
teins. Hence, the lipoprotein cholesterol concentration does
not always correspond to lipoprotein concentration [11,
12]. Unlike lipoprotein cholesterol, the lipid-transporting
apolipoprotein (apo), apoB, remains with the lipoproteins
without undergoing any changes [12]. ApoB is an essen-
tial structural component of very low-density lipoproteins,
intermediate-density lipoproteins, and low-density lipopro-
teins. Because each particle of these lipoproteins contains
one molecule of apoB, the total atherogenic particles number
can be accurately estimated by measuring the plasma level
of this apoprotein. In contrast, apoA-I, the major struc-
tural constituent of antiatherogenic high-density lipopro-
teins, exchanges between lipoproteins and the number of
apoprotein molecules varies between lipoprotein particles.
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Nevertheless, levels of apoA-I in plasma are strongly cor-
related with HDL levels. Therefore, apoB and apoA-I are
assumed to be superiormarkers for lipoprotein abnormalities
[11, 13–16]. The blood levels of apoA-I and apoB in patients
with cardiovascular disease have been shown to be better dis-
criminators than high-density lipoprotein cholesterol (HDL-
C) and LDL-C levels [8, 17]. For example, in cases where
LDL-C is in the health-related reference interval, high apoB
levels may indicate an increased number of small, dense low-
density lipoprotein particles, which are the most atherogenic
particles [18–20].
Although the concentrations of apoB and apoA-I are
associatedwith cardiovascular diseasemore strongly than the
corresponding lipoprotein cholesterol fractions, the discrim-
inant value of these apoproteins in absolute terms appears to
be less than that of their ratio (the apoB/apoA-I ratio) [11].
The apoB/apoA-I ratio reflects the balance of atherogenic and
antiatherogenic lipoproteins in plasma [4, 14–16]. Multiple
clinical and epidemiological studies have confirmed that the
apoB/apoA-I ratio is a superior marker for cardiovascular
disease compared with lipids and lipoproteins or their ratios
[2–4, 23–29]. Therefore, some studies demonstrated that
the apoB/apoA-I ratio could discriminate between patients
with coronary artery disease (CAD) and those without, even
when the CAD patients had normal lipid levels [30]. The
cut-off values for the apoB/apoA-I ratio that define a high
cardiovascular risk were proposed to be 0.9 for men and 0.8
for women [14, 29].
In this study, we determined the variation limits of
the apoB/apoA-I ratio in healthy middle-aged men with
normolipidemia and the relationship of this ratio with other
lipid indexes.
2. Materials and Methods
2.1. Subjects and Sampling. Our study included 157 appar-
ently healthy men with normolipidemia. Anthropometric
measurements (height and weight) and other personal infor-
mationwere obtained during the clinical examination and the
interview. Weight was measured to the nearest 100 g using
a standard medical scale while the subjects were minimally
clothed without shoes. Height was measured to the nearest
0.5 cm in a standing position without shoes using a standard
stadiometer. The body mass index was calculated as the
weight (in kilograms) divided by the square of the height (in
meters).
Participants were excluded from the study using the
following criteria: (i) a body mass index of 30 kg/m2 or
greater; (ii) a TC concentration above 5.2mmol/L; (iii) a
triglycerides (TG) concentration above 1.8mmol/L; and (iv)
a HDL-C concentration below 0.9mmol/L. All participants
were considered to be free from serious and chronic illnesses
at the time of the recruitment. Each subject gave written
informed consent for participating in the study, which was
approved by the Ethics Committee of Institute of Physiology,
Komi Science Center, Ural Branch of Russian Academy of
Sciences.
Fasting blood samples were taken from the antecubital
vein into vacutainers (Becton Dickinson BP). Blood samples
were centrifuged and plasma was placed into Eppendorf
microcentrifuge tubes and was stored at −40∘C until analysis.
2.2. Lipid Measurements. The plasma TC and TG concentra-
tions were measured using an enzymatic method with com-
mercially available kits (Chronolab Systems, S.L. Barcelona,
Spain). The HDL-C concentration was determined by assay-
ing the cholesterol in the supernatant obtained after the
precipitation of apoB-containing lipoproteins with phospho-
tungstate/magnesium chloride. The plasma apoA-I, apoB,
and apoE concentrations were measured using an immuno-
turbidimetric method with kits (Chronolab Systems, S.L.
Barcelona, Spain). The samples were analyzed immediately
after thawing at 37∘C in a thermostatic bath. The measure-
ment of each sample was carried out in duplicate, and the
mean was calculated.The absorbance of all samples was mea-
sured on the PowerWave 200 automated spectrophotometer
(BioTek Instruments, USA).
The LDL-C was calculated according to Friedewald’s for-
mula [31]. The non-HDL-C was calculated as the difference
between the TC and HDL-C. Some clinical indicators of
lipids metabolism were computed, including the TC/HDL-C,
apoB/apoA-I, and LDL-C/apoB ratios, as well as atherogenic
index of plasma (AIP).
For calculating the LDL-C/apoB ratio, the concentration
of LDL-C is transformed of mmol/L in mg/dL. AIP was cal-
culated as a logarithm of the ratio of the molar concentration
(mmol/L) of TG to HDL-C (i.e., log [TG/HDL-C]) [32].
2.3. Statistical Analysis. The statistical analysis was per-
formed using Statistica 6.0 (Statsoft, Tulsa, USA).The contin-
uous variables in the tables are presented as the median and
interquartile range (25th and 75th percentiles). Differences
between the groups were analyzed using the Mann-Whitney
test and the chi-squared test. Correlations between the
indices were assessed using the Spearman’s rank correlation.
A value of 𝑃 < 0.05 was accepted as statistically significant.
3. Results
Themain characteristics of the studied subjects are shown in
Table 1. The subjects ranged in age from 20 to 59 years with
the average age of 36.0 years.Themedian for bodymass index
in the studied men was 24.8 kg/m2.
The median value (25%; 75%) of the apoB/apoA-I ratio
for the entire group was 0.52 (0.42; 0.78), with values ranging
from 0.19 to 2.60. By virtue of the exclusion criteria, the
plasma TC, TG, and HDL-C levels in the men varied in
the health-related reference interval. Nevertheless, of the
157 studied subjects, 30 men (19.1%) had the apoB/apoA-I
ratio above 0.9. The values of apoB and apoA-I varied
from 30.0 to 218.0mg/dL and from 50.0 to 300.0mg/dL,
respectively. According to the health-related reference values
of apoproteins [21, 22], low values of apoA-I were determined
in 14 subjects, and high values of apoBwere found in 9men of
30 subjects with the unfavourable apoB/apoA-I ratio. Seven
subjects had low levels of apoA-I along with high levels of
apoB. In the group of men with apoB/apoA-I<0.9, low values
of apoA-I and high values of apoB were observed in 33 and
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Table 1: Baseline characteristics of study participants (𝑛 = 157).
Median (25%; 75%) Min–Max
Age, years 36.0 (29.0; 45.0) 20–59
Body mass index, kg/m2 24.8 (22.6; 26.5) 18.0–29.9
TC, mmol/L 4.13 (3.58; 4.64) 2.73–5.15
TG, mmol/L 1.11 (0.87; 1.38) 0.56–1.70
HDL-C, mmol/L 1.40 (1.21; 1.56) 1.00–1.99
LDL-C, mmol/L 2.21 (1.66; 2.69) 0.42–3.68
Non-HDL-C, mmol/L 2.74 (2.14; 3.26) 1.01–4.11
TC/HDL-C 2.93 (2.48; 3.45) 1.57–4.99
ApoA-I, mg/dL 149.8 (100.8; 180.0) 50.0–300.0
ApoB, mg/dL 78.0 (56.1; 102.0) 30.0–218.0
ApoB/apoA-I 0.52 (0.42; 0.78) 0.19–2.60
ApoE, mg/dL 2.61 (1.91; 3.46) 0.48–5.54
LDL-C/apoB 1.06 (0.73; 1.46) 0.20–2.48
AIP −0.09 (−0.22; −0.01) −0.45–0.22
Values are presented as the median, interquartile range, minimum, and
maximum.
5 subjects (26.0% and 3.1% of the total cases), respectively
(Figure 1).
Table 2 compares the subjectswith apoB/apoA-I<0.9with
thosewith apoB/apoA-I>0.9.Therewere expected differences
(due to the way in which the study was designed) between
the groups in their apoB and apoA-I levels and the ratios in
which the apoproteins were used as components. The group
of the subjects with apoB/apoA-I>0.9 was characterized by
higher TG levels (+27.6%; 𝑃 = 0.004) and AIP (+50.0%;
𝑃 = 0.032) and lower apoE levels (−22.1%; 𝑃 = 0.011)
compared to the group of the men with apoB/apoA-I<0.9
(Table 2). The TC, HDL-C, LDL-C, non-HDL-C levels, and
TC/HDL-C ratio did not significantly differ between the two
groups. Nevertheless, of note, the subjects with the high
apoB/apoA-I ratio were more likely to have an atherogenic
lipid profile. Reduced levels of apoA-I in the men with the
unfavourable apoB/apoA-I ratio against the background of
invariable concentration of HDL-C may indicate a decline of
the functional properties of high-density lipoproteins. A sig-
nificant decrease of the LDL-C/apoB ratio in the subjects with
apoB/apoA-I>0.9 (compared with those with apoB/apoA-
I<0.9) reflected the presence of small, dense low-density
lipoprotein particles.
Using Spearman’s rank correlation (Table 3), TG, apoE,
and AIP were found to be significantly correlated with the
apoB/apoA-I ratio. No correlation was observed between the
apoB/apoA-I ratio and the levels of TC, HDL-C, LDL-C,
and non-HDL-C or TC/HDL-C ratio. ApoA-I did not reveal
a significant positive or negative correlation with any lipid
parameters. As expected, the plasma levels of apoB were
positively associatedwith theTC,TG, andnon-HDL-C levels,
as well as the TC/HDL-C ratio andAIP. A significant negative
correlation was also observed between apoB and apoE.
The relationship between the values of the apoB/apoA-
I ratio and the plasma apoE levels was evaluated using the
stratification of the subjects according to the quartiles of
Table 2: The plasma lipids and apolipoproteins in the groups with






Age, years 35.0 (29.0; 43.0) 39.0 (30.0; 47.0) 0.185
Body mass
index, kg/m2 24.7 (22.7; 26.5) 24.8 (21.9; 25.7) 0.813
TC, mmol/L 4.12 (3.55; 4.64) 4.24 (3.58; 4.73) 0.825
TG, mmol/L 1.05 (0.85; 1.34) 1.34 (1.06; 1.65) 0.004
HDL-C,
mmol/L 1.40 (1.21; 1.55) 1.41 (1.25; 1.58) 0.420
LDL-C,
mmol/L 2.30 (1.66; 2.70) 2.10 (1.60; 2.64) 0.478
Non-HDL-C,
mmol/L 2.74 (2.14; 3.26) 2.71 (2.06; 3.28) 0.943
TC/HDL-C 2.93 (2.50; 3.51) 2.92 (2.36; 3.25) 0.538
ApoA-I,
mg/dL 152.6 (115.0; 188.0) 102.6 (73.0; 122.4) <0.001
ApoB, mg/dL 71.0 (53.0; 89.0) 147.9 (98.9; 190.0) <0.001
ApoB/apoA-I 0.48 (0.38; 0.62) 1.36 (1.07; 1.61) <0.001
ApoE, mg/dL 2.81 (2.00; 3.55) 2.19 (1.23; 2.96) 0.011
LDL-C/apoB 1.16 (0.88; 1.59) 0.61 (0.43; 0.69) <0.001
AIP −0.10 (−0.23;
−0.01) −0.05 (−0.15; 0.04) 0.032
Values are presented as the median and interquartile range. ∗The Mann-
Whitney𝑈 test was used to estimate differences between the groups.
apoE levels, as well as the apoB/apoA-I ratio values that have
been proposed to define increased cardiovascular risk (cut-
off values >0.9) (Figure 2). The unfavourable apoB/apoA-I
ratio was more frequently observed in the subjects with the
low levels of apoE (1st and 2nd quartiles). The percentage
of the subjects with apoB/apoA-I>0.9 decreased significantly
with the progressive increase in apoE levels (𝜒2 = 8.20;
𝑃 = 0.042). In particular, in the 1st and 2nd quartiles,
these percentages were 28.2% and 27.5%, respectively; in the
3rd and 4th quartiles, they decreased to 7.7% and 12.8%,
respectively.
4. Discussion
The atherogenic lipid profile is an important risk factor
for cardiovascular disease. This profile is characterized by
elevated levels of TC, LDL-C, and TG and lowered levels of
HDL-C [33, 34]. However, these traditional lipid risk factors
are not always adequate indicators of cardiovascular risk
[35]. The most recent studies have shown that the diagnostic
accuracy of the apoB/apoA-I ratio is significantly greater than
that of any lipid parameters [2–4, 23–29].
A total of 19.1% of the studied subjects with normolipi-
demia had the apoB/apoA-I ratio that exceeded 0.9. The epi-
demiological studies have revealed that a higher apoB/apoA-I
ratio indicates a higher cardiovascular risk, such that the
cut-off value of 0.9 has been proposed to define a risk of
developing cardiovascular disease [14].Thus, our results have
shown that the unfavourable values of the apoB/apoA-I ratio
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Table 3: Spearman correlation coefficients between the apoA-I, apoB, apoB/apoA-I ratio, and other lipid parameters (𝑛 = 157).
ApoA-I ApoB ApoB/apoA-I ratio
Spearman, 𝑟 𝑃-level Spearman, 𝑟 𝑃-level Spearman, 𝑟 𝑃-level
TC 0.06 0.443 0.17 0.031 0.06 0.421
TG −0.04 0.577 0.41 <0.001 0.32 <0.001
HDL-C 0.07 0.335 −0.06 0.426 −0.07 0.362
LDL-C 0.08 0.301 0.12 0.125 0.04 0.655
Non-HDL-C 0.08 0.312 0.21 0.010 0.09 0.240
TC/HDL-C 0.08 0.302 0.21 0.009 0.12 0.139
ApoE −0.01 0.867 −0.28 <0.001 −0.19 0.012
AIP −0.02 0.797 0.42 <0.001 0.33 <0.001


































































Figure 1: Distribution of subjects depending on the apoA-I and apoB levels in the groups with apoB/apoA-I<0.9 and apoB/apoA-I>0.9.
Values of apoB>120mg/dL and apoA-I<120mg/dL have been proposed as the cut-off points defining a high cardiovascular risk [21, 22].
may be observed in subjects without atherogenic changes in
their lipid profile. Similar data have been reported by other
authors [36–39]. The results of these clinical cross-sectional
and prospective studies have shown that the apoB/apoA-I
ratio was the only lipid-related variable that differentiated
normolipidemic patientswithCAD from thosewithoutCAD.
The lipoprotein-related risk is associated with the over-
all balance between the atherogenic and antiatherogenic
lipoproteins. Several lipoprotein and apoprotein ratios or
“atherogenic indices” have been defined to express this
balance.The TC/HDL-C, apoB/apoA-I, and AIP are themost
well-known ratios indicating the balance between the athero-
genic and protective lipoproteins [35]. In the studied subjects,
the apoB/apoA-I ratio was correlated with AIP. However,
no relationship was found between the apoB/apoA-I and
TC/HDL-C ratios. It is believed that the TC/HDL-C ratio
indicates the proportion of atherogenic to antiatherogenic
lipoproteins. However, the cholesterol levels in lipopro-
teins do not always accurately reflect the concentrations of
the plasma lipoproteins. This may occur during changes
in the size and composition of the lipoprotein particles
[4]. The absence of correlation between the apoB/apoA-I
and TC/HDL-C ratios in the studied subjects indicates a
difference in the predictive power of these ratios. At the
same time, the significant positive correlation between the
apoB/apoA-I ratio and AIP was found. AIP, calculated as
log [TG/HDL-C], reflects the balance between atherogenic
and protective lipoproteins and theoretically depicts the
high-density lipoproteins esterification rate and low-density
lipoproteins size. High AIP indicates an increase in the
percentage of small high-density lipoproteins and small,





























Figure 2: Stratification of the subjects according to the quartiles
of apoE levels and the cut-off values of the apoB/apoA-I ratio.
1st quartile: apoE<1.91mg/dL; 2nd quartile: apoE from 1.91 to
2.61mg/dL; 3rd quartile: apoE from 2.62 to 3.46mg/dL; 4th quartile:
apoE > 3.46mg/dL.
AIP reflects the qualitative composition of lipoproteins, while
the apoB/apoA-I ratio shows their number. The correla-
tion between the apoB/apoA-I ratio and AIP indicates that
simultaneous changes in the number and composition of
lipoproteins were observed in the studied subjects.
Our data have demonstrated that an increase in apoB
values in the subjects with apoB/apoA-I>0.9 was not accom-
panied by a rise in the LDL-C levels. As a result, the LDL-
C/apoB ratio in the subjects with apoB/apoA-I>0.9 was
twofold less than in those with apoB/apoA-I<0.9. The low
values of the LDL-C/apoB ratio indicate the predominance of
small, dense low-density lipoprotein particles in plasma [40].
ApoB is well known to be the major apoprotein in all poten-
tially atherogenic lipoprotein particles. However, more than
90% of all apoB in the blood is found in low-density lipopro-
teins.Therefore, the LDL-C/apoB ratio provides approximate
information on low-density lipoprotein particles size [14,
35, 41]. Small, dense low-density lipoproteins are considered
to promote atherosclerosis because of their low affinity
for low-density lipoprotein receptors and susceptibility to
oxidative modification [42]. Thus, our results indicate that
the high apoB/apoA-I ratio in the normolipidemic subjects
was associated with an increase in lipid profile atherogenicity,
which occurred due to changes in the low-density lipoprotein
particles size and composition.
The present study has showed that the subjects with
apoB/apoA-I>0.9 were also characterized by higher levels of
TG and lower concentrations of apoE. This finding indicates
a disturbance in the clearance of TG-rich lipoproteins. ApoE
is known to mediate the uptake of TG-rich lipoprotein
particles via receptor-related endocytosis. There is an opti-
mal concentration of the plasma apoE that is required for
lipoprotein clearance, and too little or toomuch of the protein
can be detrimental. Too little apoE impairs the clearance
of TG-rich lipoproteins and their remnants from plasma.
Toomuch apoE stimulates very low-density lipoproteins pro-
duction in the liver and impairs lipoprotein lipase-mediated
lipolysis, leading to hypertriglyceridemia [43, 44]. We have
previously shown that the low apoE levels may contribute to
hypertriglyceridemia in residents of the European North of
Russia [45]. The results of the present study have indicated
a relationship between the unfavourable apoB/apoA-I ratio
and the low plasma apoE levels (Figure 2). Moreover, the
significant negative correlation between apoE and apoB was
found (Table 3).Thus, an increase in the apoB/apoA-I ratio in
the studied subjects may be assumed to be accompanied by
the accumulation of TG-rich lipoproteins in plasma, which
was associated with the reduced plasma very low-density
lipoproteins clearance due to the low levels of apoE.
5. Conclusions
The apoB/apoA-I ratio exceeding 0.9 may be observed even
in the subjects with normolipidemia. An increase in the
apoB/apoA-I ratio was accompanied by a rise of AIP, which
indicated simultaneous changes in the number and composi-
tion of lipoproteins in the studied subjects. The subjects with
apoB/apoA-I>0.9 were also characterized by higher levels of
TG and lower values of LDL-C/apoB ratio and concentrations
of apoE compared with the subjects with apoB/apoA-I<0.9.
On the whole, the subjects with apoB/apoA-I>0.9 had more
atherogenic lipid profile. Thus, the apoB/apoA-I ratio can be
considered as a sensitive marker of atherogenic risk.
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